Madrigal Pharmaceuticals (MDGL) Earnings Date & Reports

Key Takeaways

• Madrigal Pharmaceuticals is scheduled to report second-quarter 2026 results on Thursday, July 30, before the U.S. market opens.
• Wall Street consensus estimates point to revenue of approximately $349 million to $350 million, which would represent year-over-year growth of roughly 64%.
• Analysts expect an adjusted net loss of around $2.23 to $2.77 per share, a wider per-share deficit than the $1.90 loss posted in the same quarter last year.
• Rezdiffra, the company's flagship MASH therapy, crossed the $1.1 billion trailing-12-month sales threshold last quarter, cementing blockbuster status in a market that remains underpenetrated.
• Investors will zero in on patient-addition trends, gross-to-net pricing dynamics, and any updates to the company's spending trajectory following aggressive pipeline investments made earlier in 2026.

Earnings Context and Why It Matters

Madrigal Pharmaceuticals (NASDAQ: MDGL) is approaching its second-quarter 2026 earnings report at a pivotal moment. The company has rapidly transitioned from a clinical-stage biotech into a commercial powerhouse on the back of Rezdiffra (resmetirom), the first and only therapy approved by both the U.S. Food and Drug Administration and the European Commission for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis. With trailing-12-month net sales exceeding $1.1 billion and over 42,250 active patients on therapy as of March 31, the launch has outperformed early expectations. Yet the stock has drifted roughly 5% lower year-to-date, reflecting ongoing tension between strong top-line momentum and persistent bottom-line losses. This earnings report will test whether Rezdiffra's commercial trajectory can sustain the enthusiasm that has made MDGL one of the most closely watched names in biotech.

Earnings Expectations

For the second quarter ending June 30, 2026, consensus estimates compiled from multiple data providers point to total revenue of roughly $349 million to $350 million. At the midpoint, that implies year-over-year growth of approximately 64% from the $212.8 million reported in the second quarter of 2025. On the bottom line, analyst forecasts vary, with the consensus adjusted loss per share clustering between $2.23 and $2.77, compared with a loss of $1.90 per share in the prior-year period. The wider expected loss reflects elevated operating expenses, including the ramp-up of the endocrinology-focused sales force, direct-to-consumer marketing initiatives, and a $25 million upfront payment tied to the in-licensing of the ARO-PNPLA3 siRNA asset from Arrowhead Pharmaceuticals. It is worth noting that Madrigal's earnings have been difficult for analysts to model consistently; the company has beaten consensus EPS estimates in five of the last seven quarters, sometimes by wide margins, due to the inherent unpredictability of biotech spending patterns and gross-to-net discount realizations.

Beyond the headline numbers, investors will closely monitor net patient additions during the quarter. In the first quarter, the company added roughly 36,000 new patients, a figure management attributed partly to seasonal insurance-reset dynamics. Sustained patient growth in the seasonally more favorable second quarter will be a key barometer of underlying demand. Additionally, management previously guided that gross-to-net discounts would remain in the mid-to-high 30% range for the remainder of 2026; any deviation from that forecast could materially shift revenue recognition and profitability expectations.

AI Screener

As investors prepare for Madrigal's upcoming earnings, tools that streamline the search for actionable market ideas can be especially valuable. Tickeron's AI Screener is an AI-powered stock and ETF discovery platform designed to help traders and investors filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-driven trading signals. Rather than manually sifting through endless charts and screeners, users can leverage the platform to surface breakout candidates, emerging trends, and overlooked opportunities across sectors — including biotechnology. For those looking to complement their earnings-season research with data-driven insights, the AI Screener offers a practical starting point.

Market Reaction and Investor Sentiment

Heading into the July 30 release, market sentiment around MDGL appears cautiously optimistic but far from euphoric. The stock closed at $544.51 on July 24 and has traded in a relatively tight range over the past month, hovering between roughly $500 and $565. Analyst consensus remains predominantly bullish — 15 out of 18 covering analysts rate the stock a Strong Buy, with an average 12-month price target near $679 — yet the shares sit well below that target, reflecting skepticism about near-term profitability and the sustainability of Rezdiffra's launch trajectory. In recent weeks, BofA Securities trimmed its price target, citing intensifying competition and questions about whether early prescription momentum can be maintained, while Truist and Citizens JMP have remained constructive. The mixed signals from the analyst community, combined with insiders offloading shares in July, suggest that the market needs a clean beat on revenue and reassuring patient-growth metrics to sustain upward momentum — and may punish any sign of deceleration.

Forward Outlook and Key Factors to Monitor

Looking past the second-quarter print, several catalysts and risk factors will shape Madrigal's investment narrative through the remainder of 2026 and into 2027.

First among them is the ongoing expansion of the diagnosed MASH patient pool. Management has highlighted that the U.S. addressable market — defined as F2/F3 MASH patients seen by target specialists — has grown nearly 50% over two years to approximately 460,000, yet diagnosis rates remain just above 10%. Continued growth in disease awareness and screening rates is essential for Rezdiffra's long-term revenue runway, and investors will listen carefully for any updated market-sizing commentary during the earnings call.

Second, the pipeline investments announced earlier this year are beginning to take shape. The ARO-PNPLA3 siRNA program, targeting a genetically defined high-risk patient subgroup, is expected to enter Phase 2 combination studies following regulatory discussions. Meanwhile, the oral GLP-1 (glucagon-like peptide-1) candidate MGL-2086 is advancing through Phase 1, and six preclinical siRNA programs are in development. While these programs broaden Madrigal's long-term MASH franchise potential, they also add to R&D (research and development) expense — a key reason why management has explicitly stated that profitability is not expected in 2026.

Third, competitive dynamics are intensifying. Other therapies targeting the MASH space, including GLP-1-based approaches, are gaining ground, and Madrigal's ability to maintain first-line positioning with payers will depend on continued real-world evidence generation. The company presented encouraging cardiometabolic data at the EASL Congress in late May, showing that Rezdiffra improved atherogenic lipid profiles and liver stiffness across patient subgroups. Sustaining that data cadence will be critical as competitors build their own clinical narratives.

Finally, the Phase 3 outcomes trial in compensated MASH cirrhosis (F4C) represents a major value-inflection point. With data expected in 2027, a positive readout could approximately double Rezdiffra's addressable patient population in the U.S. alone. Investors should watch for any updates on enrollment progress or event-rate tracking, as these will signal whether the timeline remains on track.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations